uniQure (QURE) Stock Forecast & Price Target

uniQure is viewed favorably because the FDA has become more constructive on AMT-130, accepting the 3-year Phase I/II data for a BLA path in 3Q26 and potentially allowing a randomized confirmatory study versus standard of care rather than sham surgery, which materially lowers regulatory and operational risk. The company also has a credible commercial setup in Huntington’s disease, with a potential U.S. launch targeting about 6,000 patients at pricing comparable to other hospital-administered gene therapies, while Hemgenix provides proof that it can bring gene therapies to market. Beyond HD, the pipeline offers multiple shots on goal, including promising 6-month AMT-260 data with no serious adverse events and encouraging early Fabry progress, supporting a positive long-term fundamentals view.

uniQure is burdened by a highly uncertain clinical-stage profile, with commercial launch delays for HEMGENIX, execution risk across HD, Fabry, TLE, and SOD1 programs, and meaningful regulatory and intellectual property uncertainty. The bear case is reinforced by the possibility that trials fail to show sustained efficacy or reveal a safety signal, which would undermine confidence in the company’s platform and pipeline. Competition from PFE, IONS, and WVE, along with long-term pricing pressure on HEMGENIX and broader sustainability concerns around trial conduct and data transparency, further weakens the fundamental outlook.